<DOC>
	<DOC>NCT00232024</DOC>
	<brief_summary>This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.</brief_summary>
	<brief_title>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Female, 18 years or older Selfreported presence of persistent or recurrent adverse digestive symptoms consistent with dyspepsia for at least 12 weeks, not necessarily consecutive, during the previous 12 months. Abnormal upper GI endoscopy findings such as esophageal, gastric erosions or ulcers and/or duodenal ulcers/erosions. Any of the following symptoms: heartburn, epigastric pain, nausea or vomiting. Other protocoldefined inclusion/exclusion criteria may appl</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dyspepsia, gastrointestinal, tegaserod</keyword>
</DOC>